Topical Infliximab in Eyes With Penetrating Keratoplasty

What this study is about

Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.

Who can join (things the study team will check)

✅ You may be able to join if…

• Age between 18 and 80 years;
• First corneal transplant surgery;
• Capable of providing informed consent;
• Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.

🚫 You may not be able to join if…

• Active ocular infection;
• Past corneal transplant (any technique);
• Advanced glaucoma or macular disease;
• Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);
• Malignancy diagnosed in the past 5 years (any kind);
• Demyelinating disease;
• History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV);
• Pregnancy or breastfeeding;
• Allergy to infliximab or to a compound of its topical formulation;
• Significant anomaly of complete blood count or hepatic enzymes;
• Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.

Where this trial is running

• Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada

Who to contact

Zobelle Tchouaga · 514 890-8000 · zobelle.tchouaga.tongambou.chum@ssss.gouv.qc.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05180994.